Login to Your Account



Analyst: Lucentis Set To Grab 'Majority' Of Market For AMD

By Randall Osborne


Monday, July 25, 2005

Lucentis is on the march. Again.

Last week, Genentech Inc. released the detailed data from the Phase III MARINA study of Lucentis (ranibizumab) in wet age-related macular degeneration, confirming interim data disclosed in May - but the news got even better.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription